"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 3 | 0 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 6 | 3 | 9 |
| 2005 | 0 | 3 | 3 |
| 2006 | 4 | 4 | 8 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 2 | 6 |
| 2009 | 5 | 2 | 7 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 3 | 7 |
| 2012 | 8 | 2 | 10 |
| 2013 | 6 | 3 | 9 |
| 2014 | 3 | 2 | 5 |
| 2015 | 8 | 0 | 8 |
| 2016 | 3 | 2 | 5 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 3 | 1 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 May 02; 390(17):1622-1623.
-
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.
-
Lipid-Lowering Therapy in the Elderly: Are Current Guidelines a Sign of Ageism in Medical Care? J Am Coll Cardiol. 2023 04 11; 81(14):1350-1352.
-
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023 Apr 13; 388(15):1353-1364.
-
Update on management of paediatric dyslipidaemia. Curr Opin Endocrinol Diabetes Obes. 2023 02 01; 30(1):52-64.
-
What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. J Am Heart Assoc. 2021 08 17; 10(16):e020893.
-
Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
-
Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
-
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021 01 08; 67(1):143-153.
-
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Cardiovasc Drugs Ther. 2021 12; 35(6):1269-1279.